Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003 Jan;89(1):42-8.
doi: 10.1136/heart.89.1.42.

Mode of death in heart failure: findings from the ATLAS trial

P A Poole-Wilson  1 , B F Uretsky, K Thygesen, J G F Cleland, B M Massie, L Rydén; Atlas Study Group. Assessment of treatment with lisinopril and survival
Affiliations
Clinical Trial

Mode of death in heart failure: findings from the ATLAS trial

P A Poole-Wilson et al. Heart. 2003 Jan.

Abstract

Objective: To investigate markers that predict modes of death in patients with chronic heart failure.

Design: Randomised, double blind, three period, comparative, parallel group study (ATLAS, assessment of treatment with lisinopril and survival).

Patients: 3164 patients with mild, moderate, or severe chronic heart failure (New York Heart Association functional class II-IV).

Interventions: High dose (32.5 or 35 mg) or low dose (2.5 or 5 mg) lisinopril once daily for a median of 46 months.

Main outcome measures: All cause mortality, cardiovascular mortality, sudden death, and chronic heart failure death related to prognostic factors using competing risks analysis. Mode of death was classified by trialists and by an independent end point committee.

Results: Age, male sex, pre-existing ischaemic heart disease, increasing heart rate, creatinine concentration, and certain drugs taken at randomisation were markers of increased risk of all cause mortality and cardiovascular death. There were risk markers for sudden death that were different from the risk markers for death from chronic heart failure. Low systolic blood pressure at baseline, raised creatinine, reduced serum sodium or haemoglobin, and increased heart rate were associated with chronic heart failure death. Use of beta blockers or antiarrhythmic agents (mainly amiodarone) was associated with a reduced risk of sudden death, whereas long acting nitrates and previous use of angiotensin converting enzyme inhibitors were markers for increased risk.

Conclusions: The use of competing risks analysis on the data from the ATLAS study has identified variables associated with certain modes of death in heart failure patients. This approach to analysing outcomes may make it possible to predict which patients might benefit most from particular therapeutic interventions.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram showing the review process of the end point committee involved in deciding the mode of death for each patient in the ATLAS trial.
See this image and copyright information in PMC

References

    1. Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J 1997;18:208–25. - PubMed
    1. Cleland JGF, Gemmell I, Khand A, et al. Is the prognosis of heart failure improving? Eur J Heart Fail 1999;1:229–41. - PubMed
    1. Cowie MR, Wood DA, Coats AJ, et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart 2000;83:505–10. - PMC - PubMed
    1. Coats AJS, Poole-Wilson PA. The syndrome of heart failure. In: Weatherall DJ, Ledingham JGG, Warrell DA eds. Oxford textbook of medicine. Oxford: Oxford University Press, 1996:2228–38.
    1. Cowburn PJ, Cleland JG, Coats AJ, et al. Risk stratification in chronic heart failure. Eur Heart J 1998;19:696–710. - PubMed

MeSH terms